A University of Queensland start-up company, developing a potential new treatment for obesity-related liver disease, has secured a seed investment of $1.3 million from IP Group, a UK-based intellectual property business. Jetra Therapeutics Pty Ltd is developing a treatment with the potential to reverse liver damage caused by Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic […]
Read More… from Start-up gets backing for liver disease treatment
Chronic inflammatory liver disease: cell stress mechanisms identified as prognostic factor: PSC is a rare disease with a poor prognosis and can lead to cirrhosis of the liver or bile duct cancer. It affects 0.01% of the population but, even though it is rare, PSC is responsible for more than 10% of all liver transplants, […]
Chronic inflammatory liver disease: lipid-metabolism enzyme a potential factor in new treatment approach: Primary sclerosing cholangitis (PSC) is a rare, chronic, inflammatory disease of the bile ducts and is difficult to treat. Recent studies conducted by MedUni Vienna’s Division of Gastroenterology and Hepatology, under the supervision of Michael Trauner, have shown that the administration of […]
Read More… from Chronic inflammatory liver disease treatment